AbbVie Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Robert A. Michael
- Full Time Employees
- 57,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 1 North Waukegan Road North Chicago IL United States of America 60064-6400
- IPO Date
- Jan 2, 2013
- CIK
- 0001551152
- Website
- abbvie.com
- Similar Companies
- Business
- AbbVie Inc. (NYSE: ABBV) is a global research-based biopharmaceutical company that discovers, develops, manufactures and commercializes innovative medicines across immunology, oncology, neuroscience, eye care, aesthetics, virology and gastroenterology. Founded in 2013 as a spin-off from Abbott Laboratories and headquartered in North Chicago, Illinois, the company operates in more than 70 countries with approximately 55,000 employees worldwide. Its core products include Humira (adalimumab) for autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, Crohn's disease and ulcerative colitis; Skyrizi (risankizumab) and Rinvoq (upadacitinib), both interleukin inhibitors for immunology indications; Imbruvica (ibrutinib) and Venclexta (venetoclax) for oncology; Vraylar (cariprazine) for schizophrenia and bipolar disorder; Botox for aesthetics; Mavyret (glecaprevir/pibrentasvir) for hepatitis C; and Epkinly (epcoritamab) for blood cancers, among others including Duopa/Duodopa, Ubrelvy and Vyalev in neuroscience and pipeline candidates for Parkinson's disease. AbbVie markets its portfolio to patients, healthcare providers and health systems globally, with major revenue contributions from the United States and international markets. In recent developments, the company completed acquisitions of ImmunoGen for $10.1 billion in 2024 to bolster ovarian cancer treatments with Elahere, Cerevel Therapeutics for $8.7 billion to expand neuroscience, Aliada Therapeutics for $1.4 billion, Nimble Therapeutics and Capstan Therapeutics in 2024-2025 for immunology enhancements, and Gilgamesh Pharmaceuticals in 2025 for a psychiatry drug bretisilocin valued up to $1.2 billion; it also announced partnerships such as $1.64 billion with Neomorph for molecular glue degraders and licensing from Gubra for obesity treatments, alongside over 30 deals since 2024 and manufacturing expansions including a $195 million API facility and $70 million biologics site in the U.S. to support over $10 billion in domestic investments.
Fidelity Healthcare ETF vs. iShares Pharma Fund: Which Wins?
Simplify's PINK or iShares' IYH: Which Healthcare ETF Should Long-Term Investors Choose Right Now?
Here Are Thursday’s Top Wall Street Analyst Research Calls: Abbott Labs, AbbVie, Akamai Technologies, Five Below, Keurig Dr. Pepper, Salesforce, Stryker, StubHub, and More
Johnson & Johnson vs AbbVie: Safe Dividend vs Higher Yield
The Energy and Pharma Giants Quietly Funding HDV's 3% Yield, and How Safe Each One Is
AbbVie vs. CVS Health: Which Healthcare Stock Is a Better Buy in 2026?
How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance?
Pfizer vs AbbVie: What's the Better Dividend Stock for Investors in 2026?
AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?
AbbVie Inc. $ABBV Shares Sold by Contravisory Investment Management Inc.
We Said These 4 Dividend Aristocrats Could Soar. Here's How They Did, Plus 3 New Picks.
Is AbbVie Stock a Buy After Posting Strong Q2 Earnings?
3 Beaten-Down Healthcare Stocks to Buy in August
AbbVie vs. Abbott Laboratories: Which Healthcare Stock Is a Better Buy in 2026?
ABBV Stock Dips 4% Despite Robust Q2: Buy the Dip or Stay Cautious?
AbbVie Inc. $ABBV Holdings Cut by Bill Few Associates Inc.
This Stock Keeps Raising Its Dividend No Matter What the Market Does -- and Wall Street Thinks It's a Buy Right Now
Is It Worth Investing in AbbVie (ABBV) Based on Wall Street's Bullish Views?
Prediction: AbbVie Will End The Year at This Price
BDF Gestion Has $10.07 Million Holdings in AbbVie Inc. $ABBV